作者等应用重组干扰素-α_2b(rIFN-α_2b)治疗10例除输血外未经任何治疗的进展期骨髓增生异常综合征(MDS)患者。男、女各5例,年龄50—78岁,中位数70.5岁。根据FAB 分类标准,4例为原始细胞增多的难治性贫血(RAEB),3例为转变中的原始细胞增多的难治性贫血(RAEB/T)及3例为慢性粒单细胞白血病(CMML),自诊断至开始IFN 治疗的时间为1—20个月,中位数2个月。IFN 用法:每天皮下注射,开始剂量为1×10~6IU,若主观耐受良好,在4—6周内增至每天3×10~6TU。如出现严重白细胞减少(<1.5×10~9/L)或血小板减少(<30×10~9/L),将最初IFN 剂量暂时减少50%或间歇应用(每周3次)。IFN 的平均治疗时间为6个月(范围3—14个 The authors applied recombinant interferon-α2b (rIFN-α_2b) to treat 10 patients with advanced myelodysplastic syndrome (MDS) who had not undergone any treatment other than blood transfusion. 5 males and 5 females, aged 50-78 years, with a median of 70.5 years. According to the FAB classification, 4 were refractory anemia with increased blasts (RAEB), 3 were refractory anemia with increased blasts (RAEB / T) and 3 were chronic myelomonocytic leukemia (CMML ). The time from diagnosis to the initiation of IFN treatment was 1-20 months with a median of 2 months. IFN usage: daily subcutaneous injection, the initial dose of 1 × 10 ~ 6IU, subjective well-tolerated, within 4-6 weeks to 3 × 10 ~ 6TU. In the event of severe leukopenia (<1.5 × 10 -9 / L) or thrombocytopenia (<30 × 10 -9 / L), reduce the initial IFN dose temporarily by 50% or intermittently (3 times per week). The mean duration of IFN treatment was 6 months (range 3-14)